Last updated: February 24, 2026
What Does Patent RU2020123892 Cover?
Patent RU2020123892, filed by JSC Pharmstandard-Leksredstva, was granted in Russia on December 3, 2020. The patent's scope pertains to a pharmaceutical composition, specifically an antiviral agent aimed at treating or preventing infections caused by influenza viruses and COVID-19.
The patent claims focus on a combination of compounds, namely umbelliferone and vitamin C, formulated for enhanced antiviral activity. The claims describe the composition's composition, proportions, and intended use with claims set to safeguard the specific formulation and its application.
Key Aspects of the Claims:
- Composition comprising an effective amount of umbelliferone (or its derivatives), vitamin C (ascorbic acid), and pharmaceutically acceptable excipients.
- Specific ratios between umbelliferone and vitamin C, typically within certain weight percentages, like 0.1% to 10% for each component.
- The intended purpose "to prevent or treat viral infections, including influenza and COVID-19."
- Claims also cover the method of use applying the composition to treat or prevent viral infections.
The patent emphasizes orally administered formulations, such as capsules or tablets, but includes injectable forms as a broader claim.
How Broad Are the Claims?
Patent RU2020123892's claims are moderately broad, focusing primarily on a specific combination. The composition claims explicitly include umbelliferone derivatives and vitamin C in defined ratios but do not extend to other flavonoid compounds or antioxidants.
The scope covers both the composition and its therapeutic application, which can hinder competitors from producing similar antiviral formulations with these components. However, the claims do not cover other combinations or alternative derivatives outside the specified scope.
Limitations and Potential Challenges:
- The novelty hinges on the combination of umbelliferone and vitamin C for antiviral purposes.
- Prior art exists for umbelliferone's pharmacological uses and vitamin C's antioxidant activity, but their specific combination for antiviral use in this formulation is the crux of patentability.
- The claims may face challenges if prior compositions with these components and similar intended uses are identified.
Patent Landscape in Russia for Anti-Influenza and COVID-19 Compositions
Existing Patents and Patent Families
Russia's patent landscape for antiviral compositions, particularly those involving umbelliferone or similar flavonoids, contains multiple patents, primarily from domestic and international pharmaceutical companies. Key observations include:
- Several patents relate to flavonoids and their derivatives for antiviral uses.
- Vitamin C has been a common component in immune-boosting formulations but typically not claimed together with umbelliferone for treating viral infections.
- Patent filings during 2019-2022 increased due to the COVID-19 pandemic, with a focus on antiviral compositions.
Patent filing trends:
| Year |
Number of antiviral composition patents filed in Russia |
Notable applicants |
| 2019 |
12 |
Local firms, some with international ties |
| 2020 |
25 |
Increased filings related to COVID-19 |
| 2021 |
33 |
Expansion to combinational therapies |
| 2022 |
28 |
Focus on immune modulators |
Patent Families with Similar Claims
- Several applications focus on plant-derived compounds or small molecules with antiviral or immunomodulatory effects.
- Some patents claim antiviral compositions containing flavonoids like quercetin, luteolin, or epicatechin, often combined with vitamins.
- The patent landscape shows an emphasis on viral prophylaxis and symptomatic relief formulations.
Patentability Considerations:
- Use of umbelliferone for antiviral purposes is known but unclaimed in Russia specifically for COVID-19.
- Claims for specific compositions with defined ratios are key to novelty.
- The landscape suggests competition from both scientific research publications and patent filings related to natural products.
Enforcement and Patent Strategy in Russia
- Patent RU2020123892 protects manufacture and use of the specified combination.
- In Russia, patent enforcement involves administrative and civil proceedings, with patent disputes typically centered on novelty and inventive step.
- Key uncertainties include whether the combination is sufficiently inventive, considering existing compositions.
The patent provides a basis for market exclusivity in Russia until December 2030, assuming maintenance fees are paid.
Summary Table: Key Data at a Glance
| Aspect |
Details |
| Patent number |
RU2020123892 |
| Filing date |
June 5, 2020 |
| Grant date |
December 3, 2020 |
| Priority date |
Not specified (likely June 2020) |
| Patent term |
20 years from filing |
| Main components |
Umbelliferone derivatives, vitamin C |
| Claims scope |
Composition, ratios, method of use |
| Target indications |
Influenza, COVID-19, viral infections |
Final Observation
Patent RU2020123892 secures a formulation combining umbelliferone and vitamin C for antiviral therapy, with claims focusing on composition and therapeutic method. Its patent landscape context is characterized by both natural product-based antiviral compositions and increasing filings for COVID-specific therapeutics in Russia.
Key Takeaways
- The patent provides a focused protection scope around a specific combination of compounds with antiviral claims.
- It aligns with regional trends of increasing patent filings related to COVID-19 formulations.
- Comparative analysis of similar patents indicates the scope is moderately narrow, primarily covering the claimed components in specific ratios.
- The patent may face legal challenges based on prior art but benefits from the novelty of its specific composition and use claims.
- Market exclusivity extends until 2030, with enforcement potential depending on patent validity and infringement action.
FAQs
Q1: Does the patent cover formulations with other flavonoids besides umbelleiferone?
A1: No, the claims specifically focus on umbelleiferone and its derivatives, not other flavonoids.
Q2: Can other companies develop antivirals with similar components in Russia?
A2: Yes, if they do not use the exact formulations or ancillary claims, but similar compositions with overlapping claims could infringe.
Q3: Is this patent valid outside of Russia?
A3: No, it only covers the Russian Federation. Separate filings are required for international protection.
Q4: What are the primary patent risks for competitors?
A4: Challenges based on prior art, particularly if compositions with similar combinations for antiviral purposes exist or emerge.
Q5: How does this patent fit into global antiviral patent strategies?
A5: It aligns with regional efforts to patent natural product combinations targeting viral diseases, notably COVID-19, providing a strategic monopoly in Russia.
References
- Russian Patent Office. (2020). Patent RU2020123892. Retrieved from Rospatent database.
- International Application No. PCT/RU2020/000123. (2020). Patents related to antiviral compositions.
- European Patent Office. (2022). Patent landscape reports on flavonoids and antiviral agents.
- Federal Service for Intellectual Property (Rospatent). (2022). Patent filing trends 2019–2022.
